Pharmacology of the AMPA antagonist 2,3-Dihydroxy-6-Nitro-7-Sulfamoylbenzo-(F)-Quinoxaline

Annals of the New York Academy of Sciences

Volumn 825, Issue , 1997, Pages 394-402

  Ikonomidou, Chrysanthy ^a   Turski, Lechoslaw ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; BRAIN INJURY; CONFERENCE PAPER; CONTROLLED STUDY; CONVULSION; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RAT; SEIZURE; TRANQUILIZING ACTIVITY;

ANIMALIA;

EID: 0030778296     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb48450.x     Document Type: Conference Paper

References (19)

1. ARMITAGE, P. 1971. Statistical Methods in Medical Research. Blackwell, Oxford.
2. CAMPOCHIARO, P. & J. T. COYLE. 1978. Ontogenic development of kainate neurotoxicity: correlates with glutamatergic innervation. Proc. Natl. Acad. Sci. USA 75: 2025-2029.
3. CAVALHEIRO, E. A., M. R. DEFEO & G. F. RICCI. 1983. Intracortical and intrahippocampal injections of kainic acid in developing rats: an electrographic study. Electroencephalogr. Clin. Neurophysiol. 56: 480-486.
4. CROUCHER, M. J., J. F. COLLINS & B. S. MELDRUM. 1982. Anticonvulsant action of excitatory amino acid antagonists. Science 216: 899-901.
5. DIXON, W. J. & A. M. MOOD. 1948. A method for obtaining and analyzing sensitivity data. J. Am. Statist. Assoc. 43: 109-112.
6. HONORÉ, T. 1989. Excitatory amino acid receptor subtypes and specific antagonists. Med. Res. Rev. 9: 1-23.
7. HONORÉ, T., S. DAVIES, J. DREJER, E. J. FLETCHER, P. JACOBSEN, D. LODGE & F. E. NIELSEN. 1988. Quinoxalinediones: potent competitive non-NMD A glutamate receptor antagonists. Science 241: 701-703.
8. IKONOMIDOU, C. & L. TURSKI. 1996. Neurodegenerative disorders: clues from glutamate and energy metabolism. Crit. Rev. Neurobiol. 10: 239-263.
9. KAUFMAN, B. A. & R. G. DACEY. 1994. Acute care management of closed head injury in childhood. Pediatr. Ann. 23: 18-28.
10. LAURIDSEN, J., T. HONORÉ & P. KROGSGAARD-LARSEN. 1985. Ibotenic acid analogues. Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic acid receptors. J. Med. Chem. 28:668-672.
11. LITCHFIELD, J. T. & F. WILCOXON. 1949. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96: 99-103.
12. RACINE, R. J. 1972. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32: 281-294.
13. SCHEHR, R. S. 1996. New treatments for acute stroke. Nat. Biotech. 14: 1549-1554.
14. SHEARDOWN, M. J., E. O. NIELSEN, A. J. HANSEN, P. JACOBSEN & T. HONORÉ. 1990. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247: 571-574.
15. STEPHENS, D. N. & W. KEHR. 1985. β-Carbolines can enhance or antagonise the effects of punishment in mice. Psychophamacology 85: 143-147.
16. STEPHENS, D. N., B. S. MELDRUM, R. WEIDMANN, C. SCHNEIDER & M. GRÜTZNER. 1986. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity? Psychopharmacology 90: 166-169.
17. TURSKI, L. 1990. N-Methyl-D-aspartate receptor complex: different sites for regulation and clinical consequences. Drug Res. 40: 511-514.
18. TURSKI, L., P. JACOBSEN, T. HONORÉ & D. N. STEPHENS. 1992. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J. Pharmacol. Exp. Ther. 260: 742-747.
19. TURSKI, L., D. N. STEPHENS, L. H. JENSEN, E. N. PETERSEN, B. S. MELDRUM, S. PATEL, J. BONDO HANSEN, W. LÖSCHER, H. H. SCHNEIDER & R. SCHMIECHEN. 1990. Anticonvulsant action of the β-carboline abecarnil: studies in rodents and baboon, Papio papio. J. Pharmacol. Exp. Ther. 253: 344-352.